Short Interest in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Drops By 56.2%

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) was the target of a large decline in short interest in January. As of January 15th, there was short interest totaling 1,927 shares, a decline of 56.2% from the December 31st total of 4,399 shares. Based on an average daily trading volume, of 11,509 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 11,509 shares, the short-interest ratio is presently 0.2 days.

Rocket Pharmaceuticals Stock Up 1.9%

NASDAQ:RCKTW traded up $0.00 on Friday, hitting $0.02. The stock had a trading volume of 10,000 shares, compared to its average volume of 10,347. Rocket Pharmaceuticals has a 52 week low of $0.01 and a 52 week high of $0.09. The business’s fifty day moving average is $0.02 and its 200 day moving average is $0.03.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.

Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.